A phase 1 safety and immunogenicity study of the Pharmexa-Epimmune HIV-1 CTL epitope-based DNA vaccine (EP HIV-1090) administered using a Biojector 2000 needle free immunization device in HIV-1 infected individuals receiving potent combination antiretroviral therapy (ART)

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 03 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs EP 1090 (Primary)
Indications HIV infections; HIV-1 infections
Focus Adverse reactions
Sponsors Epimmune

Most Recent Events

17 Dec 2007 Status changed from recruiting to in progress. Updated from ClinicalTrials.gov.
31 Aug 2006 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight